FR2977162B1 - Nanovecteurs ou particules polymeres et leur utilisation comme medicament et/ou agent de diagnostic - Google Patents
Nanovecteurs ou particules polymeres et leur utilisation comme medicament et/ou agent de diagnosticInfo
- Publication number
- FR2977162B1 FR2977162B1 FR1155761A FR1155761A FR2977162B1 FR 2977162 B1 FR2977162 B1 FR 2977162B1 FR 1155761 A FR1155761 A FR 1155761A FR 1155761 A FR1155761 A FR 1155761A FR 2977162 B1 FR2977162 B1 FR 2977162B1
- Authority
- FR
- France
- Prior art keywords
- nanovectors
- medicament
- polymer particles
- diagnostic agent
- diagnostic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000032 diagnostic agent Substances 0.000 title 1
- 229940039227 diagnostic agent Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000002245 particle Substances 0.000 title 1
- 229920000642 polymer Polymers 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0039—Coumarin dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1155761A FR2977162B1 (fr) | 2011-06-28 | 2011-06-28 | Nanovecteurs ou particules polymeres et leur utilisation comme medicament et/ou agent de diagnostic |
PCT/FR2012/051498 WO2013001244A1 (fr) | 2011-06-28 | 2012-06-28 | Nano vecteurs ou particules polymeres et leur utilisation comme medicament et/ou agent de diagnostic |
EP12738551.6A EP2726107A1 (fr) | 2011-06-28 | 2012-06-28 | Nano vecteurs ou particules polymeres et leur utilisation comme medicament et/ou agent de diagnostic |
US14/129,164 US20140219925A1 (en) | 2011-06-28 | 2012-06-28 | Polymer particles or nano-vectors and use thereof as a drug and/or diagnostic agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1155761A FR2977162B1 (fr) | 2011-06-28 | 2011-06-28 | Nanovecteurs ou particules polymeres et leur utilisation comme medicament et/ou agent de diagnostic |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2977162A1 FR2977162A1 (fr) | 2013-01-04 |
FR2977162B1 true FR2977162B1 (fr) | 2013-07-12 |
Family
ID=46579212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR1155761A Active FR2977162B1 (fr) | 2011-06-28 | 2011-06-28 | Nanovecteurs ou particules polymeres et leur utilisation comme medicament et/ou agent de diagnostic |
Country Status (4)
Country | Link |
---|---|
US (1) | US20140219925A1 (fr) |
EP (1) | EP2726107A1 (fr) |
FR (1) | FR2977162B1 (fr) |
WO (1) | WO2013001244A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3034538A1 (fr) * | 2014-12-18 | 2016-06-22 | Universite De Bordeaux | Particules de polymère et biomatériaux les contenant |
US20170360947A1 (en) * | 2014-12-18 | 2017-12-21 | Universite de Bordeaux | Polymer particles and biomaterials comprising the same |
AU2019285085B2 (en) | 2018-06-15 | 2024-04-18 | KWS SAAT SE & Co. KGaA | Methods for improving genome engineering and regeneration in plant II |
CN112567042B (zh) * | 2018-06-15 | 2024-10-29 | 科沃施种子欧洲股份两合公司 | 增强基因组工程化效率的方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1663469A4 (fr) * | 2003-09-05 | 2009-01-07 | Univ Massachusetts | Capsules polymeres amphiphiles et procedes associes d'assemblage interfacial |
FR2871803B1 (fr) * | 2004-06-21 | 2007-05-11 | Centre Nat Rech Scient Cnrse | Particules polymeres stimulables presentant des fonctions reactives, leur procede d'obtention, et leurs utilisations |
CA2650035C (fr) * | 2006-04-27 | 2015-02-03 | Intezyne Technologies, Inc. | Poly(ethylene glycol) contenant des endogroupes chimiquement disparates |
CA2662520A1 (fr) * | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Conjugues polymeres contenant des fragments charges positivement |
-
2011
- 2011-06-28 FR FR1155761A patent/FR2977162B1/fr active Active
-
2012
- 2012-06-28 WO PCT/FR2012/051498 patent/WO2013001244A1/fr active Application Filing
- 2012-06-28 EP EP12738551.6A patent/EP2726107A1/fr not_active Withdrawn
- 2012-06-28 US US14/129,164 patent/US20140219925A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2726107A1 (fr) | 2014-05-07 |
WO2013001244A1 (fr) | 2013-01-03 |
FR2977162A1 (fr) | 2013-01-04 |
US20140219925A1 (en) | 2014-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR21C1035I2 (fr) | Esters arylalcoyles de 4-aminopicolinates et leur utilisation comme herbicides | |
SG11201408545RA (en) | Polymer particles and use thereof | |
ZA201405501B (en) | External files for distribution of molecular diagnostic tests and determination of compatibility between tests | |
EP2934606A4 (fr) | Unités, systèmes et procédés de stérilisation | |
EP2912438A4 (fr) | Systèmes et procédés de diagnostic de santé | |
EP2912178A4 (fr) | Super-activateurs et procédés d'utilisation de ceux-ci | |
EP2901151A4 (fr) | Dispositifs et procédés de diagnostic | |
EP2920319A4 (fr) | Enzymes spécifiques de site et procédés d'utilisation associés | |
EP2714777A4 (fr) | Polymère hydrogel à base de polysaccharide et ses utilisations | |
IL231514A0 (en) | A molecular diagnostic discriminator and method for use | |
EP2608767A4 (fr) | Compositions polymères et procédés associés | |
EP2837641A4 (fr) | Polymère superabsorbant | |
FR2997406B1 (fr) | Polymere de hyaluronate et de glucomannane | |
EP2842945A4 (fr) | Dérivé de sulfonamide et utilisation médicale associée | |
EP2714817A4 (fr) | Particules polymères | |
EP2833879A4 (fr) | Inhibiteurs de kynurénine-3-monooxygénase, compositions pharmaceutiques, et procédés d'utilisation de ceux-ci | |
EP2915803A4 (fr) | Composition de polyisocyanate et composition de polymères d'isocyanate | |
HRP20171395T1 (hr) | Koncentrirane polimerne mješavine vinilaromatskih polimera i/ili vinilaromatskih kopolimera | |
EP2809510A4 (fr) | Points de polymère revêtus de polyélectrolytes et procédés associés | |
FR2999920B1 (fr) | Polymeres a empreinte moleculaire de type solgel et leur utilisation comme agent antipelliculaire | |
PT2601951E (pt) | Composição farmacêutica para o tratamento de hemorragia causada pelo distúrbio da coagulação sanguínea e sua utilização | |
EP2920588A4 (fr) | Particules traceuses et procédés de fabrication de celles-ci | |
EP2736519A4 (fr) | Compositions alcalines et leur utilisation dentaire et médicale | |
PL2582733T3 (pl) | Polimery z bocznymi grupami sacharydowymi i ich zastosowanie | |
SG11201502786TA (en) | Polymers having orthogonal reactive groups and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PLFP | Fee payment |
Year of fee payment: 6 |
|
PLFP | Fee payment |
Year of fee payment: 7 |